The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958

被引:16
作者
Andringa, G
Lubbers, L
Drukarch, B
Stoof, JC
Cools, AR
机构
[1] Univ Nijmegen, Dept Psychoneuropharmacol, Fac Med, NL-6500 HB Nijmegen, Netherlands
[2] Vrije Univ Amsterdam, Dept Neurol, Neurosci Res Inst, Amsterdam, Netherlands
来源
BEHAVIOURAL PHARMACOLOGY | 1999年 / 10卷 / 02期
关键词
MPTP; primate; Parkinsonism; dyskinesia; L-DOPA; animal model; SKF; 82958; D1; agonist;
D O I
10.1097/00008877-199903000-00006
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The aim of this study was twofold: (1) to study the predictive validity of the drug-naive, bilaterally MPTP-treated monkey as an animal model of Parkinson's disease (PD), and (2) to investigate the therapeutic and undesired effects of the D1 agonist SKF 82958 as compared to L-DOPA treatment, in drug-naive and L-DOPA pretreated monkeys. A detailed ethogram was used, allowing the separation of therapeutic and undesired effects. Eight weeks after bilateral intracarotid MPTP administration, SKF 82958 (1 mg/kg, n = 4, SKF 82958, naive group) or methyl-L-DOPA + carbi-dopa (10 + 2.5 mg/kg, n = 4, L-DOPA group) was administered intramuscularly for 22 days. After a drug-free period of eight weeks, the L-DOPA group was treated with SKF 82958 for 22 days (SKF 82959, 1 mg/kg, n=4, pretreated). All drug treatments increased the parameters used classically to evaluate dopaminergic drugs, namely body displacement, dyskinesia and dystonia. However, the new detailed analysis revealed that L-DOPA, but not SKF 82958, had therapeutic effects, reflected by an increase in goal-directed fore-limb use. SKF 82958, but not L-DOPA, induced additional undesired effects; including epileptoid behaviours in both drug-naive and drug pretreated monkeys. In one L-DOPA-unresponsive monkey, SKF 82958 did induce minor therapeutic effects, as well as undesired effects. Although the effects of SKF 82958 on fore-limb movements, rotational behaviours and body displacement were comparable in the naive and pretreated group, SKF 82958 re-initiated undesired effects in the L-DOPA pretreated group from day one. It is concluded that the bilaterally MPTP-treated monkey is an animal model with predictive validity for PD: it adequately predicts the therapeutic effects and undesired effects of L-DOPA. Furthermore, it is concluded that SKF 82958 is less effective than L-DOPA in the treatment of PD, because it did not induce therapeutic effects, but instead elicited several undesired effects. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 22 条
[1]   BEHAVIORAL INVOLVEMENT OF CENTRAL DOPAMINE D-1 AND D-2 RECEPTORS IN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE(MPTP)-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS [J].
AKAI, T ;
OZAWA, M ;
YAMAGUCHI, M ;
MIZUTA, E ;
KUNO, S .
JAPANESE JOURNAL OF PHARMACOLOGY, 1995, 67 (02) :117-124
[2]   The validity of the pretreated, unilaterally MPTP-treated monkey as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297 [J].
Andringa, G ;
Vermeulen, RJ ;
Drukarch, B ;
Renier, WO ;
Stoof, JC ;
Cools, AR .
BEHAVIOURAL PHARMACOLOGY, 1999, 10 (02) :163-173
[3]  
BLANCHET P, 1993, J PHARMACOL EXP THER, V267, P275
[4]  
BLANCHET PJ, 1996, EUR J PHARMACOL, V309, P113
[5]   A68930 - A POTENT AGONIST SELECTIVE FOR THE DOPAMINE-D1 RECEPTOR [J].
DENINNO, MP ;
SCHOENLEBER, R ;
MACKENZIE, R ;
BRITTON, DR ;
ASIN, KE ;
BRIGGS, C ;
TRUGMAN, JM ;
ACKERMAN, M ;
ARTMAN, L ;
BEDNARZ, L ;
BHATT, R ;
CURZON, P ;
GOMEZ, E ;
KANG, CH ;
STITTSWORTH, J ;
KEBABIAN, JW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 199 (02) :209-219
[6]   Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys [J].
Domino, EF ;
Ni, LS ;
Zhang, HL ;
Kohno, Y ;
Sasa, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 325 (2-3) :137-144
[7]   Selective full dopamine D-1-like (SKF-82958) and D-2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism [J].
Domino, EF .
BRAIN RESEARCH BULLETIN, 1997, 43 (01) :93-95
[8]   THE DIFFERENTIAL BEHAVIORAL-EFFECTS OF BENZAZEPINE D-1 DOPAMINE AGONISTS WITH VARYING EFFICACIES, CO-ADMINISTERED WITH QUINPIROLE IN PRIMATE AND RODENT MODELS OF PARKINSONS-DISEASE [J].
GNANALINGHAM, KK ;
HUNTER, AJ ;
JENNER, P ;
MARSDEN, CD .
PSYCHOPHARMACOLOGY, 1995, 117 (03) :287-297
[9]   DIFFERENTIAL ANTI-PARKINSONIAN EFFECTS OF BENZAZEPINE D-1 DOPAMINE AGONISTS WITH VARYING EFFICACIES IN THE MPTP-TREATED COMMON MARMOSET [J].
GNANALINGHAM, KK ;
EROL, DD ;
HUNTER, AJ ;
SMITH, LA ;
JENNER, P ;
MARSDEN, CD .
PSYCHOPHARMACOLOGY, 1995, 117 (03) :275-286
[10]   Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys [J].
Goulet, M ;
Grondin, R ;
Blanchet, PJ ;
Bedard, PJ ;
DiPaolo, T .
BRAIN RESEARCH, 1996, 719 (1-2) :129-137